References
- Hopkins J. John Hopkins University (Internet) [Internet]. Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/map.html. Accessed May 31 2021
- Dhama K, Patel SK, Pathak M, Yatoo MI, Tiwari R, Malik YS, Singh R, Sah R, Rabaan AA, Bonilla-Aldana DK, et al. An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies. Travel Med Infect Dis. 2020;37:101755.
- Hui KPY, Cheung MC, Perera RAPM, Ng KC, Bui CHT, Ho JCW, Ng MMT, Kuok DIT, Shih KC, Tsao SW, et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. Lancet Respir Med. 2020 Jul;8(7):687–95. doi:https://doi.org/10.1016/S2213-2600(20)30193-4.
- Baby B, Devan AR, Bhagyalakshmi NLRN. The impetus of COVID −19 in multiple organ affliction apart from respiratory infection: pathogenesis, diagnostic measures and current treatment strategy. Infect Disord - Drug Targets. 2020;20:1–13. doi:https://doi.org/10.2174/1871526520999200905115050.
- Adithya J, Nair B, Aishwarya TS, Nath LR. 2021. The plausible role of Indian traditional medicine in combating corona virus (SARS-CoV 2): a mini-review. Curr Pharm Biotechnol. 22(7):906–19. doi:https://doi.org/10.2174/1389201021666200807111359.
- Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol. 2016 Sep;3(1):237–61. doi:https://doi.org/10.1146/annurev-virology-110615-042301.
- Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020 Mar;367(6483):1260–63. doi:https://doi.org/10.1126/science.abb2507.
- Crowley SD, Gurley SB, Oliverio MI, Pazmino AK, Griffiths R, Flannery PJ, Spurney RF, Kim HS, Smithies O, Le TH, et al. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J Clin Invest. 2005 Apr;115(4):1092–99. doi:https://doi.org/10.1172/JCI23378.
- Patel S, Rauf A, Khan H, Abu-Izneid T. Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies. Biomed Pharmacother. 2017 Oct;94:317–25. doi:https://doi.org/10.1016/j.biopha.2017.07.091.
- Mascolo A, Sessa M, Scavone C, De Angelis A, Vitale C, Berrino L, Rossi F, Rosano G, Capuano A. New and old roles of the peripheral and brain renin-angiotensin-aldosterone system (RAAS): focus on cardiovascular and neurological diseases. Int J Cardiol. 2017 Jan;227:734–42. doi:https://doi.org/10.1016/j.ijcard.2016.10.069.
- Mascolo A, Urbanek K, De Angelis A, Sessa M, Scavone C, Berrino L, Rosano GMC, Capuano A, Rossi F. Angiotensin II and angiotensin 1-7: which is their role in atrial fibrillation? Heart Fail Rev. 2020 Mar;25(2):367–80. doi:https://doi.org/10.1007/s10741-019-09837-7.
- Li W, Zhang C, Sui J, Kuhn JH, Moore MJ, Luo S, Wong SK, Huang IC, Xu K, Vasilieva N, et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 2005 Apr;24(8):1634–43. doi:https://doi.org/10.1038/sj.emboj.7600640.
- Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020 Apr 8;8(4):e21. doi:https://doi.org/10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11. Erratum in: Lancet Respir Med. 2020 Jun;8(6):e54.
- Nguyen Q, Dominguez J, Nguyen L, Gullapalli N. Hypertension management: an update. Am Heal Drug Benefits. 2010 Jan;3(1):47–56.
- Guo J, Huang Z, Lin L, Lv J. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infe. J Am Heart Assoc. 2020 Apr;9(7):e016219. doi:https://doi.org/10.1161/JAHA.120.016219.
- Agata J, Ura N, Yoshida H, Shinshi Y, Sasaki H, Hyakkoku M, Taniguchi S, Shimamoto K. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res. 2006 Nov;29(11):865–74. doi:https://doi.org/10.1291/hypres.29.865.
- Arya VS, Kanthlal SK, Prasanth BP, Vijayakumar M; KRN &P. UD. Modulation of renin-angiotensin system by aqueous extract of large cardamom: in vitro and in silico studies. J Biol Act Prod from Nat. 2020;10(5):373–78.
- Kai H, Kai M, Niiyama H, Okina N, Sasaki M, Maeda T, Katoh A. Overexpression of angiotensin-converting enzyme 2 by renin-angiotensin system inhibitors. Truth or myth? A systematic review of animal studies. Hypertens Res; Mar 10 2021. 1–14. doi:https://doi.org/10.1038/s41440-021-00641-1.
- Clarke NE, Fisher MJ, Porter KE, Lambert DW, Turner AJ.Angiotensin converting enzyme (ACE) and ACE2 bind integrins and ACE2 regulates integrin signalling. PLoS One. 2012;7(4):e34747. doi:https://doi.org/10.1371/journal.pone.0034747.
- Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, Cooper ME. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertens (Dallas, Tex 1979). 2003 Mar;41(3):392–97. doi:https://doi.org/10.1161/01.HYP.0000060689.38912.CB.
- Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol. 2006 Nov;17(11):3067–75. doi:https://doi.org/10.1681/ASN.2006050423.
- Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000 Sep;87(5):E1–9. doi:https://doi.org/10.1161/01.RES.87.5.e1.
- Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000 Oct;275(43):33238–43. doi:https://doi.org/10.1074/jbc.M002615200.
- Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002 Jun;417(6891):822–28. doi:https://doi.org/10.1038/nature00786.
- Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett. 2002 Dec;532(1–2):107–10. doi:https://doi.org/10.1016/S0014-5793(02)03640-2.
- Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004 Jun;203(2):631–37. doi:https://doi.org/10.1002/path.1570.
- Sims AC, Baric RS, Yount B, Burkett SE, Collins PL, Pickles RJ. Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol. 2005 Dec;79(24):15511–24. doi:https://doi.org/10.1128/JVI.79.24.15511-15524.2005.
- Jia HP, Look DC, Shi L, Hickey M, Pewe L, Netland J, Farzan M, Wohlford-Lenane C, Perlman S, McCray PB Jr. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. 2005 Dec;79(23):14614–21. doi:https://doi.org/10.1128/JVI.79.23.14614-14621.2005.
- Jia HP, Look DC, Hickey M, Shi L, Pewe L, Netland J, Farzan M, Wohlford-Lenane C, Perlman S, McCray PB Jr. Infection of human airway epithelia by SARS coronavirus is associated with ACE2 expression and localization. Adv Exp Med Biol. 2006;581:479–84.
- Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003 Nov;426(6965):450–54. doi:https://doi.org/10.1038/nature02145.
- Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005 Aug;11(8):875–79. doi:https://doi.org/10.1038/nm1267.
- Li Y, Zhou W, Yang L, You R. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. Pharmacol Res. 2020 Jul;157:104833. doi:https://doi.org/10.1016/j.phrs.2020.104833.
- Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar;579(7798):270–73. doi:https://doi.org/10.1038/s41586-020-2012-7.
- Al-Sehemi AG, Olotu FA, Dev S, Pannipara M, Soliman ME, Carradori S, Mathew B. Natural Products Database Screening for the Discovery of Naturally Occurring SARS-Cov-2 Spike Glycoprotein Blockers. ChemistrySelect. 2020 Nov;5(42):13309–17. doi:https://doi.org/10.1002/slct.202003349.
- Tang T, Bidon M, Jaimes JA, Whittaker GR, Daniel S. Coronavirus membrane fusion mechanism offers a potential target for antiviral development. Antiviral Res. 2020 Jun;178:104792. doi:https://doi.org/10.1016/j.antiviral.2020.104792.
- Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, Duan G. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020 Mar;12(4). doi:https://doi.org/10.3390/v12040372.
- Lim H, Baek A, Kim J, Kim MS, Liu J, Nam KY, Yoon J, No KT. Hot spot profiles of SARS-CoV-2 and human ACE2 receptor protein protein interaction obtained by density functional tight binding fragment molecular orbital method. Sci Rep. 2020 Oct;10(1):16862. doi:https://doi.org/10.1038/s41598-020-73820-8.
- Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Hypertens Res. 2020 Jul;43(7):648–54. doi:https://doi.org/10.1038/s41440-020-0455-8. Epub 2020 Apr 27. PMID: 32341442; PMCID: PMC7184165.
- Oudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM, Butany J. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009 Jul;39(7):618–25. doi:https://doi.org/10.1111/j.1365-2362.2009.02153.x.
- Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020 Apr;181(2):271–280.e8. doi:https://doi.org/10.1016/j.cell.2020.02.052.
- Aronson JK, Ferner RE. Drugs and the renin-angiotensin system in covid-19. BMJ. 2020 Apr 2;369:m1313. doi:https://doi.org/10.1136/bmj.m1313.
- Hoffmann M, Schroeder S, Kleine-Weber H, Müller MA, Drosten C, Pöhlmann S. Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrob Agents Chemother. 2020;64. doi:https://doi.org/10.1128/AAC.00754-20.
- Coutard B, Valle C, De Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020 Apr;176:104742. doi:https://doi.org/10.1016/j.antiviral.2020.104742.
- Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol. 2002 Jan;89(2A):3A–9A. DOI:https://doi.org/10.1016/S0002-9149(01)02321-9. discussion 10A.
- Marchesi C, Paradis P, Schiffrin EL. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci. 2008 Jul;29(7):367–74. doi:https://doi.org/10.1016/j.tips.2008.05.003. Epub 2008 Jun 23.
- Garvin MR, Alvarez C, Miller JI, Prates ET, Walker AM, Amos BK, Mast AE, Justice A, Aronow B, Jacobson D. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife. 2020 Jul 7;9:e59177.
- Santos RAS, Ferreira AJ, Simões E Silva AC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol. 2008 May;93(5):519–27. doi:https://doi.org/10.1113/expphysiol.2008.042002.
- Nguyen G. Renin/prorenin receptors. Kidney Int. 2006 May;69(9):1503–06. doi:https://doi.org/10.1038/sj.ki.5000265.
- Chappell MC. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure? Hypertens (Dallas, Tex 1979). 2007 Oct;50(4):596–99. doi:https://doi.org/10.1161/HYPERTENSIONAHA.106.076216.
- Carey RM. Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertens (Dallas, Tex 1979). 2005 May;45(5):840–44. doi:https://doi.org/10.1161/01.HYP.0000159192.93968.8f.
- Bradford CN, Ely DR, Raizada MK. Targeting the vasoprotective axis of the renin-angiotensin system: a novel strategic approach to pulmonary hypertensive therapy. Curr Hypertens Rep. 2010 Aug;12(4):212–19. doi:https://doi.org/10.1007/s11906-010-0122-6.
- da Silveira KD, Coelho FM, Vieira AT, Sachs D, Barroso LC, Costa VV, Bretas TL, Bader M, De Sousa LP, Da Silva TA, et al. Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis. J Immunol. 2010 Nov;185(9):5569–76. doi:https://doi.org/10.4049/jimmunol.1000314.
- Santos RAS, Ferreira AJ, Verano-Braga T, Bader M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol. 2013 Feb;216(2):R1–17. doi:https://doi.org/10.1530/JOE-12-0341.
- Fraga-Silva RA, Pinheiro SVB, Acc G, Alenina N, Bader M, Santos RAS.The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets. Mol Med. 2008;14(1–2):28–35. doi:https://doi.org/10.2119/2007-00073.Fraga-Silva.
- Zimpelmann J, Burns KD. Angiotensin-(1-7) activates growth-stimulatory pathways in human mesangial cells. Am J Physiol Renal Physiol. 2009 Feb;296(2):F337–46. doi:https://doi.org/10.1152/ajprenal.90437.2008.
- Simões e Silva AC, Silveira KD, Ferreira AJ, Teixeira MM. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol. 2013 Jun;169(3):477–92. doi:https://doi.org/10.1111/bph.12159.
- Brojakowska A, Narula J, Shimony R, Bander J. Clinical Implications of SARS-CoV-2 interaction with renin angiotensin system: JACC review topic of the week. J Am Coll Cardiol. 2020 Jun;75(24):3085–95. doi:https://doi.org/10.1016/j.jacc.2020.04.028.
- Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, Ferrario CM. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens. 1996 Jun;14(6):799–805. doi:https://doi.org/10.1097/00004872-199606000-00017.
- Ferrario CM, Ahmad S, Groban L. Mechanisms by which angiotensin-receptor blockers increase ACE2 levels. Nat Rev Cardiol. 2020;17:378. doi:https://doi.org/10.1038/s41569-020-0387-7.
- Kriszta G, Kriszta Z, Váncsa S, Hegyi PJ, Frim L, Erőss B, Hegyi P, Pethő G, Pintér E. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on angiotensin-converting enzyme 2 levels: a comprehensive analysis based on animal studies. Front Pharmacol. 2021 Mar 8;12:619524. doi:https://doi.org/10.3389/fphar.2021.619524. PMID: 33762942; PMCID: PMC7982393.
- Ferrario CM, Jessup J, Gallagher PE, Averill DB, Brosnihan KB, Ann Tallant E, Smith RD, Chappell MC. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int. 2005 Nov;68(5):2189–96. doi:https://doi.org/10.1111/j.1523-1755.2005.00675.x.
- Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Chappell MC, Ferrario CM. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol Heart Circ Physiol. 2006 Nov;291(5):H2166–72. doi:https://doi.org/10.1152/ajpheart.00061.2006.
- Yang Z, Yu X, Cheng L, Miao LY, Li HX, Han LH, Jiang WP. Effects of enalapril on the expression of cardiac angiotensin-converting enzyme and angiotensin-converting enzyme 2 in spontaneously hypertensive rats. Arch Cardiovasc Dis. 2013 Apr;106(4):196–201. doi:https://doi.org/10.1016/j.acvd.2013.01.004.
- Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM. Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2005 Sep;289(3):H1013–9. doi:https://doi.org/10.1152/ajpheart.00068.2005.
- Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, Tikellis C, Grant SL, Lew RA, Smith AI, et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J. 2005 Feb;26(4):364–69.
- Reich HN, Oudit GY, Penninger JM, Scholey JW, Herzenberg AM. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int. 2008 Dec;74(12):1610–16. doi:https://doi.org/10.1038/ki.2008.497.
- Furuhashi M, Moniwa N, Mita T, Fuseya T, Ishimura S, Ohno K, Shibata S, Tanaka M, Watanabe Y, Akasaka H, et al. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens. 2015 Jan;28(1):15–21. doi:https://doi.org/10.1093/ajh/hpu086.
- Vuille-dit-Bille RN, Camargo SM, Emmenegger L, Sasse T, Kummer E, Jando J, Hamie QM, Meier CF, Hunziker S, Forras-Kaufmann Z, et al. Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors. Amino Acids. 2015 Apr;47(4):693–705. doi:https://doi.org/10.1007/s00726-014-1889-6.
- Emilsson V, Gudmundsson EF, Aspelund T, Jonsson BG, Gudjonsson A, Launer LJ, Lamb JR, Gudmundsdottir V, Jennings LL, Gudnason V. Serum levels of ACE2 are higher in patients with obesity and diabetes. Obes Sci Pract. 2021 Apr;7(2):239–43. doi:https://doi.org/10.1002/osp4.472.
- Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016 Aug;134(6):441–50. doi:https://doi.org/10.1161/CIRCULATIONAHA.115.018912.
- Jarari N, Rao N, Peela JR, Ellafi KA, Shakila S, Said AR, Nelapalli NK, Min Y, Tun KD, Jamallulail SI, et al. A review on prescribing patterns of antihypertensive drugs. Clin Hypertens. 2015;22:7.
- An J, Wei R, Zhou H, Luong TQ, Gould MK, Mefford MT, Harrison TN, Creekmur B, Lee MS, Sim JJ, et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use and COVID-19 infection among 824 650 patients with hypertension from a US integrated healthcare system. J Am Heart Assoc. 2021 Feb;10(3):e019669. doi:https://doi.org/10.1161/JAHA.120.019669.
- Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, Carmona-Rubio AE, Jacob M, Procop GW, Harrington S, et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 Sep;5(9):1020–26.
- Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X, Li Q, Li W, Yang S, Zhao X, et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J. 2020 Jun 7;41(22):2058–66. doi:https://doi.org/10.1093/eurheartj/ehaa433.
- Guo X, Zhu Y, Hong Y. Decreased mortality of COVID-19 with renin-angiotensin-aldosterone system inhibitors therapy in patients with hypertension: a meta-analysis. Hypertension (Dallas, Tex : 1979). 2020;76:e13–4. United States.
- Yingxia Liu FH Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients.
- Dong R, Liu P, Wee L, Butany J, Sole MJ. Verapamil ameliorates the clinical and pathological course of murine myocarditis. J Clin Invest. 1992 Nov;90(5):2022–30. doi:https://doi.org/10.1172/JCI116082.
- Li YC, Ge LS, Yang PL, Tang JF, Lin JF, Chen P, Guan XQ. Carvedilol treatment ameliorates acute coxsackievirus B3-induced myocarditis associated with oxidative stress reduction. Eur J Pharmacol. 2010 Aug;640(1–3):112–16. doi:https://doi.org/10.1016/j.ejphar.2010.04.037.
- Guang-Yi C, Li-Sha G, Yue-Chun L.Role of heart rate reduction in the management of myocarditis. Curr Pharm Des. 2018;24(3):365–78. doi:https://doi.org/10.2174/1381612824666180111105923.
- Henry C, Zaizafoun M, Stock E, Ghamande S, Arroliga AC, White HD. Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. Proc (Bayl Univ Med Cent). 2018 Oct;31(4):419–23. doi:https://doi.org/10.1080/08998280.2018.1499293.
- Mortensen EM, Nakashima B, Cornell J, Copeland LA, Pugh MJ, Anzueto A, Good C, Restrepo MI, Downs JR, Frei CR, et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis. 2012 Dec;55(11):1466–73. doi:https://doi.org/10.1093/cid/cis733. Epub 2012 Aug 23.
- Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, Yang R, Di W, Wang Z, Li Z, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerging Microbes Infect. 2020;9:757–60.
- Jung S-Y, Choi JC, You S-H, Kim W-Y. Association of renin-angiotensin-aldosterone system inhibitors with coronavirus disease 2019 (COVID-19)- related outcomes in Korea: a nationwide population-based cohort study. Clin Infect Dis. 2020 Nov 19;71(16):2121–28. doi:https://doi.org/10.1093/cid/ciaa624
- Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, Liu YM, Zhao YC, Huang X, Lin L, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020 Jun 5;126(12):1671–81. doi:https://doi.org/10.1161/CIRCRESAHA.120.317134. Epub 2020 Apr 17. Erratum in: Circ Res. 2020 Aug 28;127(6):e147.Rohit, Loomba [corrected to Loomba, Rohit].
- Li J, Chen J, Zhang H, Deng A, Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 2020 Jul;5(7):825–30. doi:https://doi.org/10.1001/jamacardio.2020.1624.
- Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A, Newman JD, Berger JS, Bangalore S, et al. Renin-angiotensin-aldosterone system inhibitors and risk of covid-19. N Engl J Med. 2020 Jun;382(25):2441–48. doi:https://doi.org/10.1056/NEJMoa2008975.
- Yang G, Tan Z, Zhou L, Yang M, Peng L, Liu J, Cai J, Yang R, Han J, Huang Y, et al. Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study. Hypertens (Dallas, Tex 1979). 2020 Jul;76(1):51–58. doi:https://doi.org/10.1161/HYPERTENSIONAHA.120.15143.
- Conversano A, Melillo F, Napolano A, Fominskiy E, Spessot M, Ciceri F, Agricola E. Renin-angiotensin-aldosterone system inhibitors and outcome in patients with SARS-CoV-2 pneumonia: a case series study. Hypertension (Dallas, Tex : 1979). 2020;76:e10–2. United States.
- Felice C, Nardin C, Di Tanna GL, Grossi U, Bernardi E, Scaldaferri L, Romagnoli M, Tonon L, Cavasin P, Novello S, et al. Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives. Am J Hypertens. 2020 Oct;33(10):944–48.
- Feng Z, Jennifer L, Yao S, Qizhi Y, Zhou W, Mao X, Huiling L, Kang W, Ouyang X, Mei J, et al. The use of adjuvant therapy in preventing progression to severe pneumonia in patients with coronavirus disease 2019: a multicenter data analysis. BMJ 2020.
- Hu J, Zhang X, Zhang X, Zhao H, Lian J, Hao S, Jia H, Yang M, Lu Y, Xiang D, et al. COVID-19 is more severe in patients with hypertension; ACEI/ARB treatment does not influence clinical severity and outcome. J Infect. 2020;81:979–97.
- Huang Z, Cao J, Yao Y, Jin X, Luo Z, Xue Y, Zhu C, Song Y, Wang Y, Zou Y, et al. The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension. Ann Transl Med. 2020 Apr;8(7):430. doi:https://doi.org/10.21037/atm.2020.03.229.
- Fosbøl EL, Butt JH, Østergaard L, Andersson C, Selmer C, Kragholm K, Schou M, Phelps M, Gislason GH, Gerds TA, et al. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA. 2020 Jul;324(2):168–77. doi:https://doi.org/10.1001/jama.2020.11301.
- Gopal K, Varma PK. Cardiac surgery during the times of COVID-19. Indian J Thorac Cardiovasc Surg. 2020 Jul;36(5):1–2. doi:https://doi.org/10.1007/s12055-020-01006-y.
- Akyüz A, Işık F, Aslan B, Çap M, Kaya İ, Ö A, Ü İ, Taştan E, Aktan A, Ö B, et al. The effect of RAAS inhibitors on acute hypoxemic respiratory failure and in-hospital mortality in the hypertensive Covid-19 patients. Clin Exp Hypertens. 2021 May:1–10. doi:https://doi.org/10.1080/10641963.2021.1916947.
- Jia H, Neptune E, Targeting CH. ACE2 for COVID-19 Therapy: opportunities and Challenges. Am J Respir Cell Mol Biol. 2021 Apr;64(4):416–25. doi:https://doi.org/10.1165/rcmb.2020-0322PS.
- Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, Raizada MK, Grant MB, Oudit GY. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ Res. 2020 May 8;126(10):1456–74. Epub 2020 Apr 8. doi:https://doi.org/10.1161/CIRCRESAHA.120.317015.
- Zoufaly A, Poglitsch M, Aberle JH, Hoepler W, Seitz T, Traugott M, Grieb A, Pawelka E, Laferl H, Wenisch C, et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir Med. 2020 Nov;8(11):1154–58. doi:https://doi.org/10.1016/S2213-2600(20)30418-5.
- de Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A, Laredo L, Laosa O, Centeno-Soto GA, Ángeles Gálvez M, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020 May 30;395(10238):1705–14. doi:https://doi.org/10.1016/S0140-6736(20)31030-8. Epub 2020 May 14.
- Kim J, Choi SM, Lee J, Park YS, Lee CH, Yim JJ, Yoo CG, Kim YW, Han SK, Lee SM. Effect of renin-angiotensin system blockage in patients with acute respiratory distress syndrome: a retrospective case control study. Korean J Crit Care Med. 2017 May;32(2):154–63. doi:https://doi.org/10.4266/kjccm.2016.00976.
- Patel AB, Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence? JAMA. 2020 May;323(18):1769–70.